**To:** 5.1.2e 5.1.2e [ 5.1.2e @rivm.nl]
**From:** 5.1.2e
**Sent:** Mon 3/1/2021 11:29:04 AM
**Subject:** commerciële organisatie
**Received:** Mon 3/1/2021 11:29:06 AM

pixelbio-exec-summary-2020.pdf
ATT00001.htm
PixelBiotech pitch deck for virus and cancer non fin info.pdf
ATT00002.htm

Hallo 5.1.2e ,

Wie kan deze mail beantwoorden?
Of mag dit gewoon naar info@...

Met vriendelijke groet,

5.1.2e   5.1.2e
   5.1.2e

**Van:** 5.1.2e < 5.1.2e @ 5.1.2e .com>
**Verzonden:** maandag 1 maart 2021 09:46
**Aan:** 5.1.2e 5.1.2e < 5.1.2e @rivm.nl>; 5.1.2e < 5.1.2e @rivm.nl>
**Onderwerp:** Pandemic analysis, cost saving and additional management possibilities

Geachte 5.1.2e , geachte 5.1.2e

We are building a new company: PixelBiotech GmbH. The company will enter the market this year with a product focusing on covid19 diagnosis as part of a new analytical infrastructure. The company is a spin off from the German National Cancer Institute at the University of Heidelberg and the Nobel Laureate (2014) Stefan Hell's lab, which is a part of the Max Planck Organisation (https://nanobiophotonics.mpibpc.mpg.de). The company is independent from large pharma or any diagnostic company.

Current main activities focus on COVID19 diagnostics and here we are here rapidly moving forward as we are part of the US initiatives to fight the COVID19 Pandemic in the US. - We are part of the NIH fast track radx-program: : https://www.nih.gov/research-training/medical-research-initiatives/radx and https://www.nih.gov/research-training/medical-research-initiatives/radx/radx-programs. The target in the US is to start with 100k tests per day, this year.

5.1.1c

It would be nice to be in contact with you and to discuss the opportunity - may we can support the Netherlands in managing the current pandemic and related healthcare cost for testing, while making things more transparent.

Met vriendelijke groeten,

5.1.2e

PS.: Attached some first information derived from presentations we prepared for investors.

5.1.2e

mail: 5.1.2e @ 5.1.2e .com
mobile (NL):
mobile (D): 5.1.2e
Web: 5.1.2e

5.1.2e